Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

WaveLight® Refractive Myopic Study

This study has been completed.
Information provided by (Responsible Party):
Alcon Research Identifier:
First received: September 10, 2013
Last updated: August 18, 2014
Last verified: August 2014

The purpose of this study is to evaluate outcomes of subjects undergoing myopic treatments using the WaveLight® Refractive Suite (Excimer EX500 and Femtosecond FS200 laser).

Condition Intervention
Refractive Error
Device: Wavelight® Refractive Suite
Procedure: LASIK surgery

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Prospective, Global, Multi-Center Study for the Evaluation of Outcomes on Subjects Undergoing Myopic Treatments Using the WaveLight® Refractive Suite

Resource links provided by NLM:

Further study details as provided by Alcon Research:

Primary Outcome Measures:
  • Uncorrected visual acuity (UCVA) [ Time Frame: Month 1 ] [ Designated as safety issue: No ]
    UCVA (ie, without spectacles) will be performed at a distance of four meters. UCVA is measured in logMAR (minimum angle of resolution), with a lower logMAR indicating better visual acuity.

Secondary Outcome Measures:
  • Corneal flap thickness as assessed by ocular coherence tomography (OCT) [ Time Frame: Up to Month 6 ] [ Designated as safety issue: No ]
    The thickness of the corneal flap will be assessed by OCT (ie, an imaging method using light to capture three-dimensional images). Corneal flap thickness is measured in microns.

  • Manifest refraction per standard of care [ Time Frame: Up to Month 6 ] [ Designated as safety issue: No ]
    A series of test lenses in graded powers will be used to determine which corrective lenses provide the sharpest, clearest vision. Manifest refraction is measured in diopters.

  • Total treatment time as documented in the log files [ Time Frame: Day 0 (surgery) ] [ Designated as safety issue: No ]
    Total treatment time with Excimer EX500 and Femtosecond FS200 lasers will be measured in seconds and minutes.

  • Spectacle independence as reported on the RSVP Questionnaire for Quality of Life and Retreatment [ Time Frame: Up to Month 6 ] [ Designated as safety issue: No ]
    The Refractive Status and Vision Profile (RSVP) Questionnaire measures self-reported vision-related health status in persons with refractive error.

  • Contrast Acuity [ Time Frame: Up to Month 6 ] [ Designated as safety issue: No ]
    Contrast acuity (ie, a measurement of the ability to see between different shades of gray from the background) will be assessed in accordance with the manufacturer's guidelines. Contrast acuity is measured in logMAR, with a lower logMAR indicating better contrast acuity.

  • Total root square mean (RMS) as determined by wavefront aberrometry [ Time Frame: Up to Month 6 ] [ Designated as safety issue: No ]
    Wavefront aberrometry measures the eye's image-forming quality and optical abnormalities and how visual acuity is affected. Total RMS (ie, the overall magnitude of all the eye's refractive errors) will be assessed using a commercially available system. Total RMS is measured in 0.01 microns.

  • Corneal curvature as measured by keratometry [ Time Frame: Up to Month 6 ] [ Designated as safety issue: No ]
    Corneal curvature will be assessed using a commercially available system. Corneal curvature is measured in diopters.

  • Wavefront optimization profile (WFO) as determined by wavefront aberrometry [ Time Frame: Up to Month 6 ] [ Designated as safety issue: No ]
    Wavefront aberrometry measures the eye's image-forming quality and optical abnormalities and how visual acuity is affected. WFO profile will be assessed using a commercially available system.

Enrollment: 99
Study Start Date: September 2013
Study Completion Date: August 2014
Primary Completion Date: January 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: WaveLight® Refractive Suite
LASIK surgery (laser in situ keratomileusis) per standard care of treatment and medication
Device: Wavelight® Refractive Suite
Excimer EX500 and Femtosecond FS200 lasers (Wavelight® Refractive Suite) used during LASIK surgery for corneal flap creation and corneal ablation
Procedure: LASIK surgery
Surgical procedure for treating refractive error based on corneal reshaping


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Willing and able to understand and sign an informed consent form.
  • Have refractive error (in both eyes) that requires refractive surgery.
  • Willing to undergo LASIK surgery using the Wavelight® Refractive Suite.
  • Myopia between 0.00 to -12.0 diopters pre-operatively.
  • Astigmatism between 0.00 to +6.00 diopters pre-operatively.
  • Willing and able to attend post-operative examinations per protocol schedule.
  • Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

  • Participation in a clinical study within the last 30 days.
  • History of previous corneal surgery in either eye.
  • Multifocal ablations in either eye.
  • PRK or PTK surgery in either eye.
  • Suffering from acute or recurring eye diseases in either eye, such as corneal ulcers, cataract, etc.
  • Any ocular disease and/or condition that, in the Investigator's clinical judgment, may put subject at significant risk, compromise study results, or interfere significantly with subject's participation in the study.
  • Unable to discontinue contact lens wear as specified in protocol.
  • History of Herpes simplex or Herpes zoster keratitis.
  • Active ocular rosacea.
  • Lyme disease.
  • History of dry eye that is unresponsive to treatment.
  • Severe ocular allergies.
  • Other medical conditions and use of medications as specified in protocol.
  • Pregnant or planning to become pregnant during the study.
  • Other protocol-specified exclusion criteria may apply.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01941498

United States, Texas
Contact Alcon Call Center for Trial Locations
Fort Worth, Texas, United States, 76134
Sponsors and Collaborators
Alcon Research
Study Director: Stefani Smith, MS Alcon Research
  More Information

No publications provided

Responsible Party: Alcon Research Identifier: NCT01941498     History of Changes
Other Study ID Numbers: A01353
Study First Received: September 10, 2013
Last Updated: August 18, 2014
Health Authority: United States: Institutional Review Board
Ireland: Research Ethics Committee
Germany: Ethics Commission

Keywords provided by Alcon Research:
refractive surgery
WaveLight processed this record on March 01, 2015